ReviewInternational journal of biological sciences2024
Three-Dimensional
Review in International journal of biological sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- Current Translational 3D In Vitro Models of Human Placental Tissue.Stem cell reviews and reports · 2026Review
- Current Perspectives on 2D and 3D Cell Culture Models in Cancer Research: Molecular Determinants of Tumor Biology and Therapeutic Response.Current issues in molecular biology · 2026Review
- Constructing anTranslational cancer research · 2026Article
- dECM bioinks for 3D bioprinted tumor models: Advances, challenges, and drug screening.iScience · 2026Review
- Spheroid cultures reveal cancer stem cell enrichment and distinct chemotherapeutic response in triple-negative breast cancer.BMC cancer · 2026Article
- Review
- Fluorescently engineered KRAS-mutant organoids as versatile tools for in vitro and in vivo cancer modeling.Biochemistry and biophysics reports · 2026Article
- Organoids in cancer therapy: translational applications and clinical promise.Molecular cancer · 2026Review
- New Insights into the Development of Papillary Thyroid Cancer: The Roles of miR-1179 and ELF3.Cells · 2026Article
- The mitochondrial translocation of phosphorylated EZH2 promotes PARP inhibitor resistance in BRCA1-deficient epithelial ovarian cancer.Cell discovery · 2026Article
- The 3D Collagen Network as a Determinant of Tumor Progression and Drug Delivery Efficiency in Breast Cancer.Pharmaceutics · 2026Review
- Heterogenous Model of Temozolomide Resistance in Glioblastoma Reveals Phenotypic Shifts in Drug Response and Migratory Potential.Advanced nanobiomed research · 2026Article
- Advances in Next-Generation Immunotherapies for Ovarian Cancer: Mechanisms of Immune Evasion and Novel Therapeutic Targets.Biomolecules · 2026Review
- Organoids glimpse: the nexus for diverse tumor heterogeneity.Frontiers in cell and developmental biology · 2026Review
- Reduced graphene oxide-incorporated gelatin-oxidized polymannose scaffold-based 3D Lung cancer model for mimicking the tumor microenvironment.Frontiers in oncology · 2026Article
- Organoids and AI-integrated models in ovarian cancer research: the future of personalized therapy.Frontiers in oncology · 2026Review
- Dissecting Cancer Metabolism and Therapeutic Resistance Using In Vitro Platforms.Advances in experimental medicine and biology · 2026Review
- Developing Mammary Gland Models for Biomedical Applications.Research (Washington, D.C.) · 2026Review
- Organoid research: new concepts and new technologies.Burns & trauma · 2026Review
- 3D bioprinted melanoma models: a novel paradigm for the assessment of anticancer strategies combining PDT and drug delivery systems.Biomedical engineering online · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer represents one of the diseases with the highest mortality rate worldwide. The burden of cancer continues to increase, not only affecting the health-related quality of life of patients but also causing an elevated global financial impact. The complexity and heterogeneity of cancer pose significant challenges in research and clinical practice, contributing to increase the failure rate of clinical trials for antitumoral drugs. This is partially due to the fact that preclinical models still present important limitations in faithfully recapitulating human tumors to serve as reliable indicators of drug effectiveness. Up to now, research and development strategies employ expensive animal models (including the so-called "humanized mice") that not only raise ethical concerns, but also frequently fail to accurately predict responses to anticancer drugs because they do not faithfully replicate human physiology as well as the patient's tumor microenvironment. On the other side, traditional two-dimensional (2D) cell cultures fail to adequately reproduce the structural organization of tumor and the cellular heterogeneity found
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.